COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
12. November 2024 07:30 ET
|
COSCIENS Biopharma Inc.
Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12,...
COSCIENS Biopharma Announces Change to Board of Directors
08. Oktober 2024 07:30 ET
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
01. Oktober 2024 17:30 ET
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
23. September 2024 07:30 ET
|
COSCIENS Biopharma Inc.
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
27. August 2024 07:30 ET
|
COSCIENS Biopharma Inc.
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation -...
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
13. August 2024 08:05 ET
|
COSCIENS Biopharma Inc.
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.
06. August 2024 18:00 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical...
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
16. Juli 2024 16:05 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13. Juni 2024 09:10 ET
|
Aeterna Zentaris Inc
Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...
Aeterna Zentaris and Ceapro Complete Merger Transaction
03. Juni 2024 09:15 ET
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two...